BNP Paribas Financial Markets’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $43.9M | Buy |
260,605
+27,105
| +12% | +$4.02M | 0.02% | 833 |
|
|
2026
Q1 | $30.8M | Buy |
233,500
+19,508
| +9% | +$2.59M | 0.01% | 916 |
|
|
2025
Q4 | $30.4M | Buy |
213,992
+113,017
| +112% | +$16.4M | 0.01% | 944 |
|
|
2025
Q3 | $14.2M | Sell |
100,975
-13,210
| -12% | -$1.79M | 0.01% | 1315 |
|
|
2025
Q2 | $14.4M | Sell |
114,185
-123,030
| -52% | -$14.1M | 0.01% | 1205 |
|
|
2025
Q1 | $26.2M | Sell |
237,215
-52,625
| -18% | -$6.67M | 0.02% | 910 |
|
|
2024
Q4 | $39.6M | Sell |
289,840
-243,484
| -46% | -$30.1M | 0.02% | 720 |
|
|
2024
Q3 | $61.4M | Buy |
533,324
+102,715
| +24% | +$14.1M | 0.04% | 439 |
|
|
2024
Q2 | $59.3M | Sell |
430,609
-1,373
| -0.3% | -$188K | 0.05% | 374 |
|
|
2024
Q1 | $59.6M | Buy |
431,982
+124,352
| +40% | +$17M | 0.05% | 375 |
|
|
2023
Q4 | $40.5M | Buy |
307,630
+29,889
| +11% | +$3.44M | 0.05% | 429 |
|
|
2023
Q3 | $31.2M | Buy |
277,741
+57,260
| +26% | +$6.03M | 0.04% | 428 |
|
|
2023
Q2 | $20.8M | Sell |
220,481
-21,201
| -9% | -$2.07M | 0.03% | 596 |
|
|
2023
Q1 | $24.5M | Buy |
241,682
+43,143
| +22% | +$4.49M | 0.03% | 510 |
|
|
2022
Q4 | $23.7M | Buy |
198,539
+68,480
| +53% | +$8.02M | 0.04% | 583 |
|
|
2022
Q3 | $13.8M | Buy |
130,059
+64,179
| +97% | +$6.51M | 0.02% | 807 |
|
|
2022
Q2 | $6.42M | Buy |
65,880
+15,254
| +30% | +$1.41M | 0.01% | 1118 |
|
|
2022
Q1 | $4.75M | Sell |
50,626
-260,316
| -84% | -$22.1M | 0.01% | 1322 |
|
|
2021
Q4 | $26.5M | Buy |
310,942
+20,406
| +7% | +$1.88M | 0.04% | 528 |
|
|
2021
Q3 | $27.9M | Sell |
290,536
-1,436
| -0.5% | -$136K | 0.04% | 475 |
|
|
2021
Q2 | $28.4M | Buy |
291,972
+153,176
| +110% | +$14.7M | 0.04% | 498 |
|
|
2021
Q1 | $13.5M | Buy |
138,796
+82,172
| +145% | +$8.62M | 0.02% | 689 |
|
|
2020
Q4 | $5.43M | Buy |
56,624
+21,067
| +59% | +$2.03M | 0.01% | 1086 |
|
|
2020
Q3 | $3.42M | Sell |
35,557
-25,923
| -42% | -$3M | ﹤0.01% | 1264 |
|
|
2020
Q2 | $7.5M | Buy |
61,480
+15,715
| +34% | +$1.74M | 0.01% | 848 |
|
|
2020
Q1 | $3.96M | Sell |
45,765
-2,862
| -6% | -$280K | 0.01% | 1092 |
|
|
2019
Q4 | $5.23M | Buy |
48,627
+37,884
| +353% | +$3.97M | 0.01% | 1164 |
|
|
2019
Q3 | $968K | Buy |
10,743
+706
| +7% | +$66K | ﹤0.01% | 1865 |
|
|
2019
Q2 | $847K | Sell |
10,037
-22
| -0.2% | -$1.81K | ﹤0.01% | 1793 |
|
|
2019
Q1 | $886K | Sell |
10,059
-9,549
| -49% | -$798K | ﹤0.01% | 1764 |
|
|
2018
Q4 | $1.4M | Buy |
19,608
+10,073
| +106% | +$965K | ﹤0.01% | 1463 |
|
|
2018
Q3 | $1.17M | Sell |
9,535
-1,181
| -11% | -$134K | ﹤0.01% | 1700 |
|
|
2018
Q2 | $1.05M | Sell |
10,716
-15,194
| -59% | -$1.36M | ﹤0.01% | 1729 |
|
|
2018
Q1 | $2.15M | Sell |
25,910
-32,074
| -55% | -$2.71M | ﹤0.01% | 1356 |
|
|
2017
Q4 | $4.5M | Sell |
57,984
-33,489
| -37% | -$2.28M | 0.01% | 1079 |
|
|
2017
Q3 | $5.61M | Buy |
91,473
+19,103
| +26% | +$1.01M | 0.01% | 766 |
|
|
2017
Q2 | $3.33M | Buy |
72,370
+57,705
| +393% | +$2.8M | 0.01% | 945 |
|
|
2017
Q1 | $635K | Buy |
14,665
+1,890
| +15% | +$81K | ﹤0.01% | 1604 |
|
|
2016
Q4 | $494K | Sell |
12,775
-1,697
| -12% | -$76.8K | ﹤0.01% | 1705 |
|
|
2016
Q3 | $733K | Buy |
14,472
+1,736
| +14% | +$86.5K | ﹤0.01% | 1032 |
|
|
2016
Q2 | $579K | Buy |
12,736
+583
| +5% | +$26.8K | ﹤0.01% | 1445 |
|
|
2016
Q1 | $481K | Sell |
12,153
-4,877
| -29% | -$194K | ﹤0.01% | 1211 |
|
|
2015
Q4 | $963K | Sell |
17,030
-429
| -2% | -$21.8K | ﹤0.01% | 1122 |
|
|
2015
Q3 | $695K | Buy |
17,459
+10,353
| +146% | +$500K | ﹤0.01% | 1202 |
|
|
2015
Q2 | $339K | Buy |
7,106
+5,100
| +254% | +$216K | ﹤0.01% | 1485 |
|
|
2015
Q1 | $79.7K | Buy |
+2,006
| New | +$71.8K | ﹤0.01% | 1793 |
|
|
2014
Q4 | – | Sell |
-4,512
| Closed | -$70.7K | – | 2765 |
|
|
2014
Q3 | $70.7K | Buy |
4,512
+4,349
| +2,668% | +$65K | ﹤0.01% | 2401 |
|
|
2014
Q2 | $2.42K | Buy |
163
+133
| +443% | +$1.88K | ﹤0.01% | 2990 |
|
|
2014
Q1 | $421 | Sell |
30
-836
| -97% | -$14.3K | ﹤0.01% | 3074 |
|
|
2013
Q4 | $8.09K | Sell |
866
-17,414
| -95% | -$170K | ﹤0.01% | 2782 |
|
|
2013
Q3 | $207K | Sell |
18,280
-4,713
| -20% | -$64.8K | ﹤0.01% | 2219 |
|
|
2013
Q2 | $308K | Buy |
+22,993
| New | +$282K | ﹤0.01% | 1971 |
|
Other funds holding NBIX
VPM
VCM
BNP Paribas Financial Markets's NBIX Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Neurocrine Biosciences (NBIX) stake by 12% in Q2 2026, buying an estimated $4.02M and bringing the position to 260,605 shares worth $43.9M. The position accounts for 0.02% of the portfolio, ranked #833.
BNP Paribas Financial Markets first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $61.4M in Q3 2024. 705 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- BNP Paribas Financial Markets held 260,605 shares of Neurocrine Biosciences worth $43.9M as of Q2 2026.
- BNP Paribas Financial Markets bought 27,105 Neurocrine Biosciences shares in Q2 2026, an estimated $4.02M.
- Neurocrine Biosciences made up 0.02% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #833 holding.
- BNP Paribas Financial Markets first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- BNP Paribas Financial Markets's Neurocrine Biosciences position peaked at $61.4M in Q3 2024.
- 705 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.